#USA #NIH Grant #Tampa #Psilera Inc. #AUD

Psilera Inc. Receives NIH Grant for Alcohol Use Disorder Research

Psilera Inc., a frontrunner in biotechnology, has recently announced its receipt of a substantial grant from the National Institutes of Health (NIH) aimed at advancing research in Alcohol Use Disorder (AUD). This grant, part of the Small Business Innovation Research program, is valued at up to $2 million over three years, reflecting a growing commitment to tackle the pressing challenges associated with alcohol addiction.

The Need for Innovative Solutions

In the United States, approximately 30 million adults are currently affected by AUD, yet only about 8% of these individuals seek treatment. This statistic highlights a significant unmet medical need for effective interventions. Psilera aims to bridge this gap by leveraging neuroplastogens—compounds believed to promote positive changes within the brain's structure and function. The promising potential of neuroplastogens lies in their ability to help patients break free from entrenched thought patterns and harmful behaviors traditionally associated with alcohol use.

Advancing Neuroplastogen Research

Dr. Jackie von Salm, Co-founder and Chief Scientific Officer of Psilera, expressed gratitude for the NIH's endorsement and funding, stating, "We are thankful to the NIH for this funding, which will enable us to quickly advance our research into AUD. Neuroplastogens hold tremendous promise in treating a range of devastating and debilitating diseases, and this endorsement further emphasizes their potential as a future addiction therapy."

Psilera's research focuses on a unique psilocybin derivative selected through extensive compound library screenings, specifically targeting the serotonin receptor 5-HT2A. Initial pre-clinical studies suggest that this innovative therapy not only holds potential as a non-opioid treatment for alcohol consumption but also has passed early safety assessments, paving the way for further testing.

Breaking Stigmas Surrounding Treatment

If successful, Psilera's novel therapy could offer a groundbreaking solution for AUD patients. With the potential for at-home administration, this treatment method promises to reduce the stigmas and burdens often associated with seeking help for alcohol-related issues. Currently, the landscape offers no non-hallucinogenic and non-addictive alternatives for treating AUD, making this research vital for many individuals in need of assistance.

The Vision of Psilera Inc.

Founded with the mission to transform the treatment landscape for neurodegenerative diseases and addiction, Psilera Inc. is at the forefront of pioneering neuroplastic therapies. Alongside its AUD initiative, the company’s development pipeline includes PSIL-006, aimed at addressing frontotemporal dementia (FTD). As Psilera continues to push the boundaries of medical innovation, it strives to provide accessible and impactful treatment options for underserved populations.

For more information about Psilera Inc. and its cutting-edge research, visit www.psilera.com.

Conclusion

With the NIH grant as a significant milestone, Psilera Inc. is positioned to lead the charge in developing novel treatment strategies for Alcohol Use Disorder. Through dedicated research and innovation, the company aims to change lives and redefine the standards of care in mental health and addiction treatment.